The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Takeda (I)
Other Relationship - Astellas Medivation; Janssen
Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.
 
Ying Zhang Mazzu
No Relationships to Disclose
 
Joshua Armenia
No Relationships to Disclose
 
Goutam Chakraborty
No Relationships to Disclose
 
Yuki Yoshikawa
No Relationships to Disclose
 
Travis A. Gerke
No Relationships to Disclose
 
Mohammad Omar Atiq
No Relationships to Disclose
 
Konrad Hermann Stopsack
No Relationships to Disclose
 
Kazumasa Komura
No Relationships to Disclose
 
Gwo-Shu Mary Lee
No Relationships to Disclose
 
Lorelei A. Mucci
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics
Consulting or Advisory Role - Bavarian Nordic; BIND Biosciences; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; Metamark Genetics; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Sanofi